It also lowers appetite and slows digestion in the stomach, helping reduce body fat
Therefore, Novo Nordisk does not conclude a causal relationship between GLP-1 RA use, semaglutide and age-related macular degeneration at this time. Dr Alison Cave, the chief safety officer of the Medicines & Healthcare products Regulatory Agency, a UK watchdog, said: Macular degeneration is not currently listed as a potential side-effect of these medicines
The guidance comes as demand for the class of drugs known as GLP-1 agonists has surged worldwide, and governments are figuring out how to include the blockbuster therapies in public health systems
By Sonia Garcia | May 23, 2025 Stress can push the brain to its limits, sometimes distorting perception and creating sensory experiences that feel real but arent
On the metabolism of exogenous ketones in humans
CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion